New drug aimed at tough breast cancer enters final testing phase

NCT ID NCT06519370

Ongoing Disease control Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a new drug called FDA018-ADC against standard chemotherapy in 350 people with advanced triple-negative breast cancer that has worsened after taxane treatment. The study compares how long the cancer stays under control and overall survival. Participants are randomly assigned to receive either the new drug or one of several standard chemotherapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FDA018-ADC (an antibody-drug conjugate)
What this could lead to: If it works, this could offer a new treatment option for people with advanced triple-negative breast cancer who have stopped responding to taxane chemotherapy.
What could go wrong: This is a late-stage trial, but the drug may still fail to improve survival or cause serious side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.